Solvay Cert Refusal Leaves FCA Circuit Split In Place

Law360, New York (June 21, 2010, 12:13 PM EDT) -- The U.S. Supreme Court refused Monday to review the dismissal of a False Claims Act suit from two former Solvay Pharmaceuticals Inc. sales representatives who accused the drugmaker of using an off-label marketing campaign to boost sales of its THC compound, leaving a split among the circuit courts.

The high court denied the workers' petition for certiorari without further comment, letting stand a December decision from the U.S. Court of Appeals for the Eleventh Circuit finding the plaintiffs' FCA allegations deficient.

Relators James Hopper and Colin...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.